drugset / Trial / NCT03995472
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in combination with SHR-1316 in patients with advanced malignancies and to provide a recommended dose (RP2D) for subsequent clinical studies.
Timeline
- Start
- 2020-02-14
- Primary completion
- 2023-01-12
- Completion
- 2023-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | Intravenous |
| Subject | SHR-1501 | Unknown | — | Subcutaneous |